Long-term efficacy update of crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumour from EORTC trial 90101 CREATE. In Onkológia. ISSN 1336-8176. Bratislava : SOLEN, 2022, 2022, roč. 17, č. 1, s. 68.